304 results on '"Maemondo M"'
Search Results
2. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
3. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)
4. P1.08D.01 The Efficacy of Durvalumab after Concurrent Chemoradiotherapy for EGFR-Mutated Stage III Non-Small Cell Lung Cancer (NEJ063)
5. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA
6. A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405
7. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer
8. FP05.05 A Prospective Observational Study of Osimertinib Using Plasma Concentrations in NSCLC With Acquired EGFR T790M Mutation
9. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy
10. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
11. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902
12. Supplement to: Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR.
13. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells
14. Tofacitinib suppressed remodeling of pulmonary eosinophilic vasculitis in a murine model
15. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival
16. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
17. A PHASE II STUDY OF ERLOTINIB MONOTHERPAY IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITHOUT EGFR GENE MUTATION WHO HAVE NEVER/LIGHT SMOKING HISTORY: NEJ006/TCOG0903
18. PHASE II STUDY OF AMRUBICIN (AMR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AS THIRD-LINE OR FOURTH-LINE CHEMOTHERAPY: HOKKAIDO LUNG CANCER CLINICAL STUDY GROUP TRIAL (HOT) 0901
19. 382MO The preliminary safety result of a phase II study of osimertinib in combination with platinum + pemetrexed in patients with previously untreated EGFR-mutated advanced NSCLC (NEJ032C/LOGIK1801: OPAL)
20. 1311P First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA
21. FRI0497 THERAPEUTIC STRATEGIES AND LONG-TERM OUTCOME IN PATIENTS WITH INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES: A SINGLE CENTER LARGE-SCALE OBSERVATIONAL COHORT STUDY
22. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis
23. A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
24. P2.14-52 The Results from Plasma EGFR Mutation Analysis in NEJ026 Study
25. A phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial
26. Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026
27. OA 10.01 Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays
28. P2.06-009 Trace Elements Affect Lung Cancer Subtypes
29. P1.03-005 Phase 2 Study of Ceritinib in Patients with ALK+ NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9
30. OA 05.08 Final Result of Phase I/II Study (AF-001JP) of Alectinib, a Selective CNS-Active ALK Inhibitor, in ALK+ NSCLC Patients (Pts)
31. EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs)
32. 521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
33. EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment
34. NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations
35. KEYNOTE-025: Phase 1b study of pembrolizumab (pembro) in Japanese patients (pts) with previously treated PD-L1+ non-small cell lung cancer (NSCLC)
36. 1491P - A phase II study of trastuzumab monotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial
37. 1441P - Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026
38. 3065 A phase II study of chemotherapy combined with bevacizumab for patients with malignant pleural effusions: North East Japan Lung Cancer Study Group Trial NEJ013A
39. 3067 Randomized phase II trial of standard daily administration versus alternate-day administration of S-1 in patients with advanced non-small cell lung cancer: North Japan Lung Cancer Group Trial NJLCG1102
40. 521 Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)
41. 3064 NEJ016: Phase II study of carboplatin and weekly paclitaxel plus bevacizumab followed by bevacizumab for highly selected elderly non-squamous non-small cell lung cancer patients
42. 420O - EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs)
43. Small cell lung cancer and progressive retinopathy
44. Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC
45. Final Result of Randomized Phase 2 Trial Comparing Amrubicin (A) with Re-Challenge of Platinum Doublet (P) in Patients (Pts) with Sensitive-Relapsed Small-Cell Lung Cancer (Sclc): Njlcg0702
46. Randomized Phase Ii Study of Concurrent Versus Sequential Alternating Gefitinib and Chemotherapy in Previously Untreated Non-Small Cell Lung Cancer (Nsclc) with Sensitive Egfr Mutations: Nej005/Tcog0902
47. The Effect of Prophylactic Cranial Irradiation (Pci) in the Patients with Extensive-Disease Small-Cell Lung Cancer (Ed-Sclc): Results of a Japanese Randomized Phase III Trial
48. Updated Data on Clinical and Molecular Profile of Surgically Resected Small Cell Lung Cancer: Intergroup Study with Fight002 and Hot1301
49. Final Results of a Randomized Phase 2 Study Comparing Carboplatin Plus Irinotecan (Ci) Versus Carboplatin Plus Amrubicin (Ca) for Extensive Disease Small-Cell Lung Cancer: Njlcg0901
50. [Non-small-cell lung cancer (NSCLC) in an elderly patient--a case of squamous cell carcinoma successfully treated with chemotherapy using vinorelbine]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.